Several listed companies in Shanghai and Shenzhen issued important announcements on March 18. The following is a summary of good news:
Apeloa Pharmaceutical Co.Ltd(000739) : MPP authorizes Apeloa Pharmaceutical Co.Ltd(000739) and other 35 pharmaceutical enterprises to produce Pfizer’s oral covid-19 therapeutic drugs
Apeloa Pharmaceutical Co.Ltd(000739) ( Apeloa Pharmaceutical Co.Ltd(000739) ) announced on March 18. Recently, MPP (the “drug patent pool organization”) issued an announcement and relevant media reports. MPP authorized Apeloa Pharmaceutical Co.Ltd(000739) and other 35 pharmaceutical enterprises to produce Pfizer’s oral covid-19 therapeutic drugs. This license is non exclusive; The licensed areas are 95 low-income countries or regions such as India, Pakistan and Vietnam, excluding China.
Tasly Pharmaceutical Group Co.Ltd(600535) : Huoxiang Zhengqi dropping pills and other products are listed in covid-19 pneumonia diagnosis and treatment plan (trial version 9)
Tasly Pharmaceutical Group Co.Ltd(600535) ( Tasly Pharmaceutical Group Co.Ltd(600535) ) March 18th announcement, recently, the office of the national health and Health Committee and the office of the State Administration of traditional Chinese medicine jointly issued the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth). The company’s and company’s control group’s “Xiang Xiang Zheng Qi dripping pills” is listed as the recommended medicine during the medical observation period. Xingnaojing injection is listed as a heavy and dangerous recommendation. Angong Niuhuang Pill is listed as the recommended drug for severe cases.
Jiangsu Sidike New Materials Science & Technology Co.Ltd(300806) : proposed to cooperate with Suzhou Anjie Technology Co.Ltd(002635) Shehe Hydrogen Energy Technology Co., Ltd.
Jiangsu Sidike New Materials Science & Technology Co.Ltd(300806) ( Jiangsu Sidike New Materials Science & Technology Co.Ltd(300806) ) announced on March 18 that the company plans to jointly invest with Suzhou Anjie Technology Co.Ltd(002635) to establish a joint venture Suzhou andick Hydrogen Energy Technology Co., Ltd. the company signed an investment agreement with Suzhou Anjie Technology Co.Ltd(002635) on matters related to this foreign investment on March 17, 2022. The registered capital of the joint venture is proposed to be 24 million yuan, of which Jiangsu Sidike New Materials Science & Technology Co.Ltd(300806) subscribed 10.8 million yuan, accounting for 45% Suzhou Anjie Technology Co.Ltd(002635) subscribed capital contribution of 13.2 million yuan, accounting for 55%. This investment is conducive to expanding the core parts business of hydrogen fuel cell.
Zhejiang Orient Gene Biotech Co.Ltd(688298) : covid-19 virus antigen detection reagent added Japanese PMDA sales license and Saudi MDMA certification
Zhejiang Orient Gene Biotech Co.Ltd(688298) ( Zhejiang Orient Gene Biotech Co.Ltd(688298) ) announced on March 18 that the company’s covid-19 virus antigen detection reagent (including self-test) has added Japanese PMDA sales license and Saudi MDMA certification on the basis of obtaining EU CE certification, US FDA certification, China nmpa certification and corresponding markets; And New Coronavirus nucleic acid test kit (direct fluorescent PCR) added Thailand certification, is conducive to expanding the international market, serving the international COVID-19 virus epidemic prevention needs. In addition, the company added the US fda510k certification of group A Streptococcus rapid detection reagent (pharyngeal swab), which further enriched the company’s product types of respiratory disease detection reagents in the US market on the basis of obtaining the US fdaeua certification or market access of covid-19 antibody / antigen detection reagent. In addition, the company added five new nmpa class III medical device registration certificates for drug detection series reagents.
Beijing Shunxin Agriculture Co.Ltd(000860) 5 1, raise part of the price of Baijiu
Beijing Shunxin Agriculture Co.Ltd(000860) ( Beijing Shunxin Agriculture Co.Ltd(000860) ) March 18th announcement, decided by the company, based on the original price, according to the different quality grades, with net content 500ml as the accounting unit, Qingxiang Baijiu: raised 3 yuan to 15 yuan; Luzhou Baijiu: raised 10 yuan to 15 yuan. The price adjustment is planned to be implemented from May 1, 2022.
Eve Energy Co.Ltd(300014) : selected as the supplier of Bosch to provide lithium-ion power battery for Bosch
Eve Energy Co.Ltd(300014) ( Eve Energy Co.Ltd(300014) ) it was announced on March 18 that the company had recently received a notice from Robert Bosch GmbH (hereinafter referred to as “Bosch”) about the supplier’s fixed point. The company was selected as the supplier of Bosch to provide Bosch with lithium-ion power batteries for auxiliary applications of electric vehicles in the global market.
China Meheco Group Co.Ltd(600056) : the company completes the import customs clearance procedures of the first batch of Pfizer covid-19 drugs
China Meheco Group Co.Ltd(600056) ( China Meheco Group Co.Ltd(600056) ) issued a notice on March 18th, which signed an agreement with Pfizer Inc. The company will be responsible for the commercial operation of Pfizer Inc COVID-19 virus treatment PAXLOVID in Chinese mainland market in the period of agreement (2022). The product is included in the ninth edition of the diagnosis and treatment plan, but has not entered the national medical insurance for the time being. If it is included in the national medical insurance, it may have an impact on the sales price. The final use and sales of the product are affected by factors such as epidemic prevention and control, and there is great uncertainty. It is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance. On March 17, the company completed the import customs clearance procedures of the first batch of this product and is fully cooperating with the state in the fight against covid-19 epidemic.
Tongkun Group Co.Ltd(601233) : it is proposed to repurchase shares with RMB 500 million to RMB 1 billion
Tongkun Group Co.Ltd(601233) ( Tongkun Group Co.Ltd(601233) ) announced on March 18 that it is planned to buy back shares by means of centralized bidding transaction for the later implementation of employee stock ownership plan or equity incentive plan, or conversion of convertible corporate bonds issued by listed companies. The total amount of repurchase funds shall not be less than 500 million yuan, not more than 1 billion yuan, and the repurchase price shall not exceed 25.00 yuan / share.
Autobio Diagnostics Co.Ltd(603658) : it is proposed to repurchase shares with RMB 150 million to RMB 300 million
Autobio Diagnostics Co.Ltd(603658) ( Autobio Diagnostics Co.Ltd(603658) ) announced on March 18 that the company plans to buy back the company’s shares in the form of centralized bidding transaction for the implementation of employee stock ownership plan or equity incentive. The proposed repurchase amount is not less than 150 million yuan and not more than 300 million yuan, and the repurchase price is not more than 60 yuan / share.
Ningxia Building Materials Group Co.Ltd(600449) : the controlling shareholder plans to increase its holdings by 70 million yuan to 100 million yuan
Ningxia Building Materials Group Co.Ltd(600449) ( Ningxia Building Materials Group Co.Ltd(600449) ) announced on March 18 that the controlling shareholder China Building Materials Co., Ltd. plans to increase its shares in the company, with an increase of no less than 70 million yuan and no more than 100 million yuan.
